Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Person

Steve N. Slilaty

Tracked across 3 events · 19 articles · First seen May 18, 2026 · Last active Jun 25, 2026

Sentiment
30
Attention
4
Events
3
Relationships
4
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
3 30
Business
Impact: Steve N. Slilaty, CEO of Sunshine Biopharma, expressed satisfaction with the approval of Rivaroxaban, highlighting its importance for the company's generics market position.
Jun 01, 2026 · 6 articles
4 60
Regulatory
Impact: Steve N. Slilaty, CEO of Sunshine Biopharma, expressed satisfaction with the approval of Anastrozole, highlighting its importance for the company's generics portfolio and commitment to affordable medicines.
Jun 25, 2026 · 6 articles
3 0
Business
Impact: Dr. Steve N. Slilaty, CEO of Sunshine Biopharma, authorized the board to consider a reverse stock split.
May 18, 2026 · 7 articles
Sunshine Biopharma ceo Steve N. Slilaty Steve N. Slilaty is the founder, Chairman, and Chief Executive Officer of Sunshi
Sunshine Biopharma Steve N. Slilaty
Canada Steve N. Slilaty
Canada Steve N. Slilaty
ERGEN INTELLIGENCE
Track Steve N. Slilaty live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.